ARS Pharmaceuticals, Inc.
SPRYNASDAQHealthcare● Active
$8.99
+$0.43(+5.02%)
Market Cap$892736325
P/E Ratio—
52W High$18.9
52W Low$6.66
ARS Pharmaceuticals, Inc. (SPRY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SPRY · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.61
Est. -$0.53 · -15.1%
Revenue
$0.02B
Est. $0.02B · +2.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
SPRY reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.62
Rev. $1.20B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.62
Rev. Est.$1.20B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.49 | — | — | — | $0.03B | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.53 | -$0.61 | -15.1% | $0.02B | $0.02B | +2.2% |
| — Q1 FY2026 | Mar 9, 2026 | -$0.42 | -$0.42 | +0.0% | $0.03B | $0.03B | +9.7% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.45 | -$0.52 | -15.6% | $0.03B | $0.03B | +27.0% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$0.41 | -$0.46 | -12.2% | $0.02B | $0.03B | -43.2% |
| — Q2 FY2025 | May 14, 2025 | -$0.35 | -$0.35 | +0.0% | $0.01B | $0.01B | -45.8% |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$0.04 | $0.52 | +1400.0% | $0.09B | $0.01B | +574.4% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.18 | -$0.20 | -11.1% | $0.00B | $0.02B | -87.9% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.49
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.61
EPS Est.
-$0.53
EPS Surpr.
-15.1%
Revenue
$0.02B
Q1 FY2026
Mar 9, 2026
EPS Actual
-$0.42
EPS Est.
-$0.42
EPS Surpr.
+0.0%
Revenue
$0.03B
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.52
EPS Est.
-$0.45
EPS Surpr.
-15.6%
Revenue
$0.03B
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$0.46
EPS Est.
-$0.41
EPS Surpr.
-12.2%
Revenue
$0.02B
Q2 FY2025
May 14, 2025
EPS Actual
-$0.35
EPS Est.
-$0.35
EPS Surpr.
+0.0%
Revenue
$0.01B
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
$0.52
EPS Est.
-$0.04
EPS Surpr.
+1400.0%
Revenue
$0.09B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.20
EPS Est.
-$0.18
EPS Surpr.
-11.1%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.14 | $0.16 | $0.18 | 1 |
| Q3 FY2028 | $0.37 | $0.42 | $0.48 | 1 |
| Q2 FY2028 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q1 FY2028 | $-0.36 | $-0.31 | $-0.27 | 1 |
| Q4 FY2027 | $-0.24 | $-0.21 | $-0.18 | 1 |
| Q3 FY2027 | $-0.07 | $-0.06 | $-0.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -15.1% | $7.94 | $7.43 | -6.42% |
| ▲ Q1 FY2026 | Mar 9, 2026 | +0.0% | $9.06 | $9.05 | -0.11% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -15.6% | $8.85 | $8.88 | +0.34% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -12.2% | $16.66 | $15.82 | -5.04% |
| ▲ Q2 FY2025 | May 14, 2025 | +0.0% | $13.35 | $12.10 | -9.36% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +1400.0% | $11.65 | $14.31 | +22.83% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -11.1% | $16.61 | $14.08 | -15.23% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -8.3% | $9.32 | $9.78 | +4.94% |
Q2 FY2026-6.42%
Report Date
May 15, 2026
EPS Beat/Miss
-15.1%
Price Before
$7.94
Price After
$7.43
Q1 FY2026-0.11%
Report Date
Mar 9, 2026
EPS Beat/Miss
+0.0%
Price Before
$9.06
Price After
$9.05
Q4 FY2025+0.34%
Report Date
Nov 10, 2025
EPS Beat/Miss
-15.6%
Price Before
$8.85
Price After
$8.88
Q3 FY2025-5.04%
Report Date
Aug 13, 2025
EPS Beat/Miss
-12.2%
Price Before
$16.66
Price After
$15.82
Q2 FY2025-9.36%
Report Date
May 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$13.35
Price After
$12.10
Q1 FY2025+22.83%
Report Date
Mar 20, 2025
EPS Beat/Miss
+1400.0%
Price Before
$11.65
Price After
$14.31
Q4 FY2024-15.23%
Report Date
Nov 13, 2024
EPS Beat/Miss
-11.1%
Price Before
$16.61
Price After
$14.08
Q3 FY2024+4.94%
Report Date
Aug 6, 2024
EPS Beat/Miss
-8.3%
Price Before
$9.32
Price After
$9.78
Avg Beat Reaction+4.45%
Avg Miss Reaction-4.28%
Beat Rate3 / 8 quarters
Largest Move+22.83% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SPRY ends December
ARS Pharmaceuticals, Inc. (SPRY) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.61 — missing the analyst consensus of $-0.53 by -15.1%. The next SPRY earnings date is expected around September 1, 2026.
Each quarter, investors track SPRY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SPRY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SPRY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SPRY earnings · 5 questionsARS Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. SPRY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SPRY historically reports after market close (AMC).
SPRY earnings datewhen is SPRY earningsSPRY next earnings datewhen does SPRY report earningsSPRY earnings calendar
▸ Source: FMP · ARS Pharmaceuticals, Inc. SEC filings · US GAAP · ARS Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026